Association between polymorphisms of OGG1, EPHA2 and age-related cataract risk: a meta-analysis.
BACKGROUND
Evidences have identified the correlation of 8-oxoguanine DNA glycosylase-1 (OGG1) and eph-receptor tyrosine kinase-type A2 (EPHA2) polymorphisms in age-related cataract (ARC) risk. However, the results were not consistent. The objective of this study was to examine the role of these two gene polymorphisms in ARC susceptibility.


METHODS
Eligible case-control studies published between January 2000 and 2015 were searched and retrieved in the electronic databases. The odds ratio with 95 % confidence interval (CI) was employed to calculate the strength of the relationship.


RESULTS
We totally screened out six articles, including 5971 cataract patients and 4189 matched controls. Three variants were contained (OGG1 rs1052133; EPHA2 rs7543472 and rs11260867). For OGG1 rs1052133, we detected a significant correlation between OGG1 polymorphism and ARC risk under the heterogenous model (CG vs. CC: OR = 1.34, 95 % CI = 1.06-1.70, P = 0.01) and dominant model (GG+CG vs. CC: OR = 1.45, 95 % CI = 1.16-1.81, P = 0.001), especially in patients with cortical cataract of subgroup analysis by phenotypes (P < 0.05). For EPHA2 rs7543472 and rs11260867, we did not find a positive association between these two mutations and ARC susceptibility in total cases. Subgroup analysis by phenotypes of cataract showed that only in cortical cataract, genotypes of rs7543472 under the allele model, homogenous model and recessive model; genotypes of rs11260867 under the heterogenous model and dominant model were associated with ARC risk.


CONCLUSIONS
OGG1 rs1052133 (CG and CG+GG genotypes) might be risk factor for ARC, particularly in cortical cataract risk. EPHA2 rs7543472 (T allele and TT genotype) and rs11260867 (CG and GG+CG genotypes) might be associated with cortical cataract.
Department of Ophtalmology, Hangzhou First People's Hospital, Hangzhou Hospital Affiliated to Nanjing Medical University, Huansha Road No. 261, Hangzhou, 310006, Zhejiang, People's Republic of China.
Hongxu
H
Zhang
Department of Ophtalmology, Hangzhou First People's Hospital, Hangzhou Hospital Affiliated to Nanjing Medical University, Huansha Road No. 261, Hangzhou, 310006, Zhejiang, People's Republic of China.
Jianguang
J
Zhong
Department of Orthopaedics, Hangzhou First People's Hospital, Hangzhou Hospital Affiliated to Nanjing Medical University, Hangzhou, 310006, Zhejiang, People's Republic of China.
Zhenyu
Z
Bian
Department of Central Laboratory, Hangzhou First People's Hospital, Hangzhou Hospital Affiliated to Nanjing Medical University, Hangzhou, 310006, Zhejiang, People's Republic of China.
Xiang
X
Fang
Department of Surgical Oncology, Hangzhou First People's Hospital, Hangzhou Hospital Affiliated to Nanjing Medical University, Hangzhou, 310006, Zhejiang, People's Republic of China.
You
Y
Peng
Department of Ophtalmology, Hangzhou First People's Hospital, Hangzhou Hospital Affiliated to Nanjing Medical University, Huansha Road No. 261, Hangzhou, 310006, Zhejiang, People's Republic of China. huypkf@163.com.
Yongping
Y
Hu
Age-related cataract; EPHA2; Meta-analysis; OGG1; Polymorphism
Antioxid Redox Signal. 2014 Feb 1;20(4):708-26
23901781
Br J Ophthalmol. 2012 May;96(5):614-8
22133988
Mol Vis. 2014 May 21;20:661-9
24868140
PLoS One. 2012;7(8):e42120
22916121
J Biol Chem. 2014 Jul 11;289(28):19694-703
24825902
Acta Ophthalmol. 2010 May;88(3):358-66
19222399
Mutagenesis. 2012 Jul;27(4):501-10
22451681
Annu Rev Pharmacol Toxicol. 2015;55:465-87
25292427
Mol Vis. 2010 Mar 24;16:511-7
20361013
Age (Dordr). 2013 Dec;35(6):2435-44
23334603
PLoS Genet. 2009 Jul;5(7):e1000584
19649315
ACS Chem Biol. 2015 Oct 16;10(10):2334-43
26218629
PLoS One. 2012;7(5):e36564
22570727
Mol Vis. 2009 Nov 24;15:2448-63
19956408
Curr Eye Res. 2015;40(8):815-21
25310012
Brain Res Mol Brain Res. 1995 Apr;29(2):325-35
7609620
Ophthalmology. 2012 May;119(5):900-6
22306120
Hum Mutat. 2009 May;30(5):E603-11
19306328
Mol Vis. 2008;14:2042-55
19005574
Free Radic Biol Med. 2013 Oct;63:401-9
23726996
Exp Eye Res. 2015 Jun;135:102-8
25660075
Cancer Res. 2016 Jan 1;76(1):30-4
26586787
PLoS One. 2012;7(3):e33001
22412971
Cancer Res. 2015 Aug 15;75(16):3327-39
26130649
Curr Eye Res. 2015 Apr;40(4):378-85
24911554
J Cell Sci. 2013 Mar 15;126(Pt 6):1488-97
23378024
Annu Rev Public Health. 1996;17:159-77
8724222
Sci China Life Sci. 2012 May;55(5):434-43
22645087
Invest Ophthalmol Vis Sci. 2013 Dec 13;54(14):ORSF5-ORSF13
24335069
Rev Prat. 2013 Jan;63(1):43-7
23457826
Invest Ophthalmol Vis Sci. 2013 Feb 01;54(2):1201-7
23322570
Ophthalmology. 2012 Dec;119(12):2463-70
22921386
Mol Vis. 2011;17:1553-8
21686326
Oncogene. 1998 Jun 25;16(25):3219-25
9681819
Invest Ophthalmol Vis Sci. 2013 Apr 26;54(4):3010-8
23572101
Expert Opin Ther Targets. 2011 Jan;15(1):31-51
21142802
Ophthalmic Genet. 2016;37(1):14-8
24673449
DNA Repair (Amst). 2013 Dec;12(12):1094-104
24075420
Ophthalmic Epidemiol. 2007 Jul-Aug;14(4):173-8
17896293
Ophthalmology. 2015 Nov;122(11):2179-85
26278859
PLoS One. 2013 Aug 16;8(8):e71003
23976972
Invest Ophthalmol Vis Sci. 2013 Sep 05;54(9):5989-94
23887802
Antioxid Redox Signal. 2014 Aug 10;21(5):700-4
24527727
Ophthalmology. 2015 Nov;122(11):2169-78
26256834
PLoS One. 2013 Aug 27;8(8):e72518
24014202
Dis Markers. 2015;2015:690878
26089588
Clin Genet. 2013 Aug;84(2):120-7
23647473
Geriatrics. 2009 May;64(5):19-22, 25-6
19435391
J Ophthalmol. 2015;2015:401894
26664742
Oftalmologia. 2006;50(2):3-9
16927750
Arch Ophthalmol. 1993 Jun;111(6):831-6
8512486